Table 1.
Univariate and multivariate analysis of factors influencing the pre-treatment serum ALP activity.
| Factors | Pre-treatment serum ALP | χ2-test P value | Logistic P value | OR (95%CI) | |
|---|---|---|---|---|---|
| Normal | Elevated | ||||
| Sex | 0.312 | ||||
| Male | 270 (81.1%) | 63 (18.9%) | |||
| Female | 134 (84.8%) | 24 (15.2%) | |||
| Age | 0.745 | ||||
| <60 | 91 (81.3%) | 21 (18.7%) | |||
| ≥60 | 313 (82.6%) | 66 (17.4%) | |||
| Tumor site | 0.296 | ||||
| Upper | 46 (70.7%) | 11 (19.3%) | |||
| Middle | 239 (83.7%) | 47 (16.3%) | |||
| Low | 119 (70.4%) | 29 (19.6%) | |||
| Tumor diameter | 0.032 | 0.017 | 2.642 (1.335~4.213) | ||
| <3 | 232 (85.6%) | 39 (14.4%) | |||
| ≥3 | 172 (78.2%) | 48 (21.8%) | |||
| T classification | 0.030 | 0.043 | 1.746 (1.069~2.758) | ||
| T1 | 102 (90.3%) | 11 (9.7%) | |||
| T2 | 170 (82.5%) | 36 (17.5%) | |||
| T3 | 79 (78.2%) | 22 (21.8%) | |||
| T4 | 53 (64.6%) | 18 (25.4%) | |||
| N classification | 0.020 | 0.065 | 1.878 (0.725~3.113) | ||
| N0 | 98 (88.3%) | 13 (11.7%) | |||
| N1 | 102 (85.0%) | 18 (15.0%) | |||
| N2 | 119 (82.6%) | 25 (17.4%) | |||
| N3 | 85 (73.3%) | 31 (26.7%) | |||
| TNM stage | 0.026 | 0.005 | 4.592 (2.238~7.851) | ||
| I | 82 (90.1%) | 9 (9.9%) | |||
| II | 172 (83.5%) | 34 (16.5%) | |||
| III | 150 (77.3%) | 44 (22.7%) | |||
| Differentiation | 0.930 | ||||
| Moderate and high | 286 (82.2%) | 62 (17.8%) | |||
| Poor | 118 (82.5%) | 25 (17.5%) | |||
| Pathological type | 0.156 | ||||
| Adenocarcinoma | 349 (83.3%) | 70 (16.7%) | |||
| Signet cell carcinoma | 55 (76.4%) | 17 (23.6%) | |||